AHRQ Patient Safety Network ► FDA Drug Safety Communication: FDA warns about prescribing and dispensing errors resulting from brand name confusion with antidepressant Brintellix (vortioxetine) and antiplatelet Brilinta (ticagrelor).

AHRQ Patient Safety Network





FDA Drug Safety Communication: FDA warns about prescribing and dispensing errors resulting from brand name confusion with antidepressant Brintellix (vortioxetine) and antiplatelet Brilinta (ticagrelor).

MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; July 30, 2015.

Look-alike and sound-alike drug names can contribute to confusion and result in medication errors. To raise awareness of potential wrong-patient errors due to similarity between two proprietary names, this announcement describes near misses with the drugs at the prescribing and dispensing stage and suggests clinicians use the generic names for the medications to reduce risk of patient harm.

Free full text 
Information 

Related Resources

MEETING/CONFERENCE PROCEEDINGS

Public Meeting on Improving Patient Safety by Enhancing the Container Labeling for Parenteral Infusion Drug Products.

US Food and Drug Administration, Center for Drug Evaluation and Research. January 11, 2007.

PRESS RELEASE/ANNOUNCEMENT

ReliOn insulin syringes for use with U-100 insulin (Tyco Healthcare-Covidien).

MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; November 6, 2008. 

STUDY

Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002.

Wysowski DK, Swartz L. Arch Intern Med. 2005;165:1363-1369.

PRESS RELEASE/ANNOUNCEMENT

Safety warnings regarding use of fentanyl transdermal (skin) patches.

FDA Public Health Advisory. Silver Spring, MD: US Food and Drug Administration; December 21, 2007.

View all related resources...